Skip to content

Contact +44 (0) 20 7060 7474 email us

Oncology

Oncology Market Leaders

Analyses and Outlook, Market Report 2008 - 2023

Publication Date October 2008
Publisher Visiongain
Product Type Report
Pages 201
ISBN Number not applicable
Product Code VIS00087

Price

£1,499.00
approximately: $2,270 | €1,673

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said.

Cancer Research UK said it raised questions about whether NICE's system of appraisal was appropriate for all types of drugs, especially when there were few alternative treatments. NICE argues it has to make tough choices when deciding which drugs should be paid for and which not.

Modern targeted drugs are revolutionising cancer care, yet they often increase survival by only a few months. Drug companies argue they need to charge a high price for them to make a return on risky research investment.

The high price of treatment with the kidney drugs means it would cost GBP71,500 to GBP171,300 ($139,800-335,000) for every year of healthy life gained, NICE calculated.

Today there are an estimated 24.6 million people in the world living with cancer. The World Health Organisation (WHO) has predicted that the worldwide incidence will rise by 50% between 2000 and 2020. Cancer is becoming increasingly common in developing and developed countries, with significant potential for market expansion in both regions. Worldwide, there remain significant unmet needs in cancer treatment, with great opportunities for companies who can develop safer and better-targeted treatments. Our new report Oncology Market Leaders - Analyses and Outlook, 2008-2023, will help you to understand those developments and their significance.

According to IMS, sales data for 2007, the oncology area ranked as the fifth-largest therapeutic class worldwide. In 2007, the anti-cancer drug market generated sales of $66.8bn, up by 17% in comparison with $57bn in 2006. MabThera/Rituxan, Herceptin and Avastin - leading products of biotechnology and pharmacogenomics - are currently amongst the most prominent drugs in cancer therapy. Furthermore, the cancer pipeline remains strong. Current and future R&D is likely to produce significant therapeutic advances, especially when combined with pharmacogenomic medicine, particularly theranostics.

Oncology Market Leaders - Analyses and Outlook, 2008-2023, examines the product portfolios of the leading companies in oncology critically, with in-depth analysis, especially market forecasting and qualitative analyses of market drivers and restraints. This report also contains primary research from our survey of experts in the field. The result is a comprehensive market-based report with detailed analyses and informed opinion.

Why you should buy this report: In particular, this report concentrates on the following essential aspects of that market:

  • Detailed analysis of the current oncology market - achievements and present challenges
  • Sales forecasts for the oncology market from 2008-2023
  • Sales forecasts for the leading 10 drugs in that market from 2008-2023
  • Detailed analyses of the leading companies in this market segment
  • Discussions of issues affecting the oncology market
  • Drivers and opportunities in the oncology market
  • Restraints and threats facing the oncology market
  • Competitor analysis and outlook for the market from 2008-2023
  • Pipeline developments and their implications for the future.

The oncology market will continue to generate high revenues and significant profitability in the years ahead, visiongain concludes. Sales of the leading cancer drugs are increasing worldwide, with greater reliance on those agents as time goes by. Certainly, the future prospects for the major players in the oncology market are highly promising, especially with the dawn of more-personalised molecular medicine promising greater efficacy and safety, particularly in cancer treatment. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.a

Contents

  • 1. Executive Summary
    • Oncology Market Leaders - Analyses and Outlook, 2008-2023
  • 2. Overview of Cancer
    • 2.1 Cancer Incidence is Rising
      • 2.1.1 The Most Common Cancers
      • 2.1.2 Worldwide Variation in Cancer Incidence and Mortality
    • 2.2 Cancer Biology
    • 2.3 Treatments for Cancer
      • 2.3.1 Chemotherapy
        • 2.3.1.1 Antimetabolites
        • 2.3.1.2 Alkylating Agents
        • 2.3.1.3 Cytotoxic antibiotics
        • 2.3.1.4 Vinca Alkaloids
    • 2.4 Oncology Market was the Fifth-Largest Therapeutic Area In 2007
    • 2.5 Anti-Neoplastic Drugs Account for 50% Revenues of the Oncology Market
  • 3. Market Forecast for the Top 10 Cancer Drugs
    • 3.1 Top-10 Cancer Drugs Accounted for 35% Oncology Market Revenues
      • 3.1.1 MabThera Leads Top-10 Anti-Neoplastic Drugs Market Share
    • 3.2 MabThera
      • 3.2.1 MabThera's Market Sales Forecast, 2008-2023
      • 3.2.2 Development of MabThera
    • 3.3 Herceptin
      • 3.3.1 Herceptin Market Sales Forecast, 2008-2023
      • 3.3.2 Development of Herceptin
    • 3.4 Avastin
      • 3.4.1 Avastin Market Sales Forecast, 2008-2023
      • 3.4.2 Development of Avastin
    • 3.5 Glivec
      • 3.5.1 Glivec Market Sales Forecast, 2008-2023
      • 3.5.2 Development of Glivec
    • 3.6 Taxotere
      • 3.6.1 Taxotere Market Sales Forecast, 2008-2023
      • 3.6.2 Development of Taxotere
    • 3.7 Eloxatin
      • 3.7.1 Eloxatin Market Sales Forecast, 2008-2023
      • 3.7.2 Development of Eloxatin
    • 3.8 Arimidex
      • 3.8.1 Arimidex Market Sales Forecast, 2008-2023
      • 3.8.2 Development of Arimidex
    • 3.9 Gemzar
      • 3.9.1 Gemzar Market Sales Forecast, 2008-2023
      • 3.9.2 Development of Gemzar
    • 3.10 Caxodex
      • 3.10.1 Casodex Market Sales Forecast, 2008-2023
      • 3.10.2 Development Casodex
    • 3.11 Erbitux
      • 3.11.1 Erbitux Market Sales Forecast, 2008-2023
      • 3.11.2 Development Erbitux
    • 3.11 Top-10 Anti-Neoplastic Drugs High Revenue Streams Will Continue Through 2008-2023
  • 4. Cancer Market SWOT Analysis
    • 4.1 The World Biopharmaceutical Market Continues to Grow, But Faces Mounting
      • Challenges
    • 4.2 The Continuing Success of International Biopharmaceuticals Companies is
      • Dependent Upon Important Drivers and Restraints
    • 4.3 Companies Are Gradually Changing Their Strategic Focus to Overcome
      • Challenges in the Worldwide Market
    • 4.4 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
    • 4.5 Driving and Restraining Forces Acting Upon the Cancer Market
      • 4.5.1 A SWOT Analysis for Cancer Market
    • 4.6 Unmet Medical Needs for Cancer Remain the Major Restraint in this Market
    • 4.7 Patient Potential to Drive Anti-Neoplastic Market
    • 4.8 Spiralling Worldwide Rate of Cancer Will Continue to Create Revenue
      • Opportunities for Biopharmaceutical Companies
    • 4.9 Over 1 million Cases of Cancer Will be Diagnosed in the US in 2008 4.10
      • Over 3 million Cases of Cancer are Diagnosed in Europe Yearly
    • 4.11 There is Marked Growth in Cancer in Key Emerging Markets
    • 4.12 Sedentary Lifestyle Increases the Global Cause of Certain Cancers
      • 4.12.1 Tobacco Smoking Leading Cause of Lung Cancer
      • 4.12.2 Current Policy & Expansion of Smoking Bans Kick Off in Leading
        • Markets
      • 4.12.3 Obesity Raises the Risk of Certain Types of Cancer
      • 4.12.4 Obesity Rates Rise Sharply In Developed Nations
    • 4.13 The Need for New Drugs is Imperative before Cancer Attains Chronic
      • Disease Status
    • 4.14 Market Opportunities for New Cancer Therapies
      • 4.14.1 Biomarkers will be Key in Early Diagnosis of Cancers
      • 4.14.2 The Growing Investor Interest in Pharmacogenomics Holds Revenue
        • Prospects for Cancer Drugs
      • 4.14.3 Pharmacogenomics Holds Potential Benefits
    • 4.15 Will Advancement in Technology Rejuvenate the Blockbuster Business
      • Model for Anti-cancer Drugs Market Leaders?
    • 4.16 PLM Strategies Will Be Imperative in Driving Sales of Cancer Products
    • 4.17 Increased Combination Therapies Will Expand Revenues of Cancer
      • Medicines
    • 4.18 New Reformulation of Existing Products will be Significant in the Face
      • of Rising Competition
    • 4.19 The Cancer Vaccine Market Holds Revenue Prospects
      • 4.19.1 Wide Use of Prophylactic Cancer Vaccines Will Rise Accordingly 4.20
        • Kinase-Based Anticancer Drug Screening Gain Momentum
    • 4.21 Increasing Use of Pharmacoeconomic Evaluations Will Have an Impact on
      • Future Revenues of Cancer Medicines
    • 4.22 Will Major Players in Oncology Market Continue to Take More Commercial
      • Risks
    • 4.23 The Need for Greater R&D Efficiency Will Remain as One of the Key
      • Priorities for Leading Companies
    • 4.24 Lifestyle Modification will be Key in the Prevention of Cancers
    • 4.25 Research Collaborations Will Hold Prominence if the Market is to Expand
    • 4.26 Experts' Views on Main Issues in the Cancer Area
  • 5. Key Players & Pipeline
    • 5.1 Key Players in the Oncology Market Account for 70% of Global Revenues in 2007
      • 5.1.1 Roche is the Market Leader in Cancer Therapeutics
    • 5.2 Roche's R&D Pipeline
      • 5.2.1 Roche Has Over 20 Phase III Studies for Oncology Underway
      • 5.2.2 Roche has Over Six Molecules in Phase II Oncology Studies
      • 5.2.3 Roche's Phase I Oncology Pipeline is Dominated by Small Molecule
        • Agents
    • 5.3 Sanofi- Aventis' R&D Pipeline
      • 5.3.1 Sanofi-Aventis Has a Dynamic Phase III Oncology Pipeline
      • 5.3.2 Sanofi-Aventis' Phase II Oncology Pipeline to Largely Target Breast
        • Cancer
      • 5.3.3 Sanofi-Aventis' Phase I Oncology Pipeline
    • 5.4 Amgen's R&D Pipeline
      • 5.4.1 Amgen Has an Impressive Phase III Oncology Pipeline
      • 5.4.2 Amgen's Phase II Oncology Pipeline
      • 5.4.3 Amgen's Phase I Oncology Pipeline
    • 5.5 Novartis' R&D Pipeline
      • 5.5.1 Novartis Will File for New Cancer Drugs Before 2010
      • 5.5.2 Novartis' Phase II Oncology Pipeline
      • 5.5.3 Novartis' Phase I Oncology Pipeline
    • 5.6 AstraZeneca's R&D Pipeline
      • 5.6.1 AstraZeneca's Oncology Pipeline
      • 5.6.2 AstraZeneca has Two Candidates in Phase III Studies for NSCLC
      • 5.6.3 AstraZeneca's Phase II Oncology Pipeline
      • 5.6.4 AstraZeneca's Phase I Oncology Pipeline
    • 5.7 Johnson & Johnson's R&D Pipeline
      • 5.7.1 J&J's Phase III Oncology Pipeline
      • 5.7.2 J&J's Phase II Oncology Pipeline
      • 5.7.3 J&J's Phase I Oncology Pipeline
    • 5.8 Schering-Plough's R&D Pipeline
      • 5.8.1 Schering-Plough's Phase III Oncology Pipeline
      • 5.8.2 Schering-Plough's Phase II Oncology Pipeline
      • 5.8.3 Schering-Plough's Phase I Oncology Pipeline
    • 5.9 Pfizer's R&D Pipeline
      • 5.9.1 Pfizer's Oncology Pipeline
      • 5.9.2 Pfizer's Phase III Oncology Portfolio
      • 5.9.3 Pfizer's Phase II Oncology Portfolio
      • 5.9.4 Pfizer's Phase I Oncology Portfolio 5.10 Eli Lilly's R&D Pipeline
      • 5.10.1 Eli Lilly's Phase III Oncology Pipeline
      • 5.10.2 Eli Lilly's Phase II Oncology Pipeline
      • 5.10.3 Eli Lilly's Phase I Oncology Pipeline
    • 5.11 Merck KGaA's R&D Pipeline
      • 5.11.1 Merck KGaA's Phase III Oncology Pipeline
      • 5.11.2 Merck KGaA's Phase II Oncology Pipeline
      • 5.11.3 Merck KGaA's Phase I Oncology Pipeline
  • 6. Oncology World Market Analysis
    • 6.1 The Global Oncology Market CAGR Reaches 13% from 2004-2007
      • 6.1.1 Global Oncology Market Sales Forecast, 2008-2023
    • 6.2 Oncology Market Analysis in Seven Major Markets
      • 6.2.1 US Oncology Market Analysis
      • 6.2.2 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
      • 6.2.3 US Oncology Market Sales Forecast, 2008-2023
    • 6.3 Japan's Oncology Market Analysis
      • 6.3.1 Sales ($m) in Japan's Oncology Market by Therapeutic Class, 2004-2007
      • 6.3.2 Japan Oncology Market Sales Forecast, 2008-2023
    • 6.4 The Leading EU Oncology Markets Analysis
      • 6.4.1 France Leads the EU Anticancer Drugs Market
        • 6.4.1.1 France's Oncology Market Analysis
        • 6.4.1.1 France's Oncology Market Analysis
        • 6.4.1.2 Sales ($m) in France's Oncology Market by Therapeutic Class,2004-2007
        • 6.4.1.3 France's Oncology Market Sales Forecast, 2008-2023
    • 6.5 Germany's Oncology Market Analysis
      • 6.5.1 Sales ($m) in Germany's Oncology Market by Therapeutic Class, 2004-2007
      • 6.5.2 German Oncology Market Sales Forecast, 2008-2023
    • 6.6 Italy's Oncology Market Analysis
      • 6.6.1 Sales ($m) in Italy's Oncology Market by Therapeutic Class, 2004-2007
      • 6.6.2 Italy's Oncology Market Sales Forecast, 2008-2023
    • 6.7 Spain's Oncology Market Analysis
      • 6.7.1 Sales ($m) in Spain's Oncology Market by Therapeutic Class, 2004-2007
      • 6.7.2 Spain's Oncology Market Sales Forecast, 2008-2023
    • 6.8 UK Anticancer Oncology Market
      • 6.8.1 Sales ($m) in UK's Oncology Market by Therapeutic Class, 2004-2007
      • 6.8.2 UK Oncology Market Sales Forecast, 2008-2023
    • 6.9 Emerging Markets
      • 6.9.1 China Leads the Oncology Market in Emerging Countries
      • 6.9.2 Emerging Market & RoW Oncology Market Sales Forecast, 2008-2023
  • 7. Most Interesting Developments
    • 7.1 Biotech Drugs (Monoclonal Antibodies) in Cancer Treatment Rise Sharply
      • in Leading Pipelines
    • 7.2 R&D Trends in Kinase-Inhibitory Anticancer Drugs Widens
  • 8. Conclusions
    • 8.1 The Oncology Market Was the Fifth Largest Therapeutic Area in 2007
    • 8.2 High Revenue Streams of the Top-10 Cancer Drugs Will Continue Through 2008-2023
    • 8.3 Roche Leads the Way in R&D for Anticancer Drugs
    • 8.4 World Market for Oncology Will Expand Significantly During 2008-2023
    • 8.5 Most Interesting Developments
    • 8.6 The Oncology Market Has Great Potential to Drive Year-On-Year Revenue Growth
  • List of Tables
    • Table 2.1 The Most Common Cancers Worldwide by Cancer Site
    • Table 2.2 Rates of Common Cancers in Developed and Developing Nations
    • Table 2.3 Leading Antimetabolite Drugs in Oncology
    • Table 2.4 Leading Alkylating Drugs in Oncology
    • Table 2.5 Leading Cytotoxic Antibiotics in Drugs in Oncology
    • Table 2.6 Leading Vinca Alkaloid Drugs in Oncology
    • Table 2.7 Global Therapeutic Market, 2007
    • Table 2.8 Global Oncology Market Revenues by Therapeutic Class, 2007
    • Table 3.1 Top-10 Oncology Drugs: Total Sales, 2008-2023
    • Table 3.2 Sales of Top 10 Anti-Neoplastic Drugs, 2007
    • Table 3.3 Global Sales of MabThera, 2004-2007
    • Table 3.4 MabThera: Total Sales, 2008-2023
    • Table 3.5 Global Sales of Herceptin, 2004-2007
    • Table 3.6 Herceptin Market Sales Forecast, 2008-2023
    • Table 3.7 Global Sales of Avastin, 2004-2007
    • Table 3.8 Avastin Market Sales Forecast, 2008-2023
    • Table 3.9 Global Sales of Glivec, 2004-2007
    • Table 3.10 Glivec Market Sales Forecast, 2008-2023
    • Table 3.11 Global Sales of Taxotere, 2004-2007
    • Table 3.12 Taxotere Market Sales Forecast, 2008-2023
    • Table 3.13 Global Sales of Eloxatin, 2004-2007
    • Table 3.14 Eloxatin Market Sales Forecast, 2008-2023
    • Table 3.15 Global Sales of Arimidex, 2004-2007
    • Table 3.16 Arimidex Market Sales Forecast 2008-2023
    • Table 3.17 Global Sales of Gemzar, 2004-2007
    • Table 3.18 Gemzar Market Sales Forecast, 2008-2023
    • Table 3.19 Global Sales of Casodex, 2004-2007
    • Table 3.20 Casodex Market Sales Forecast, 2008-2023
    • Table 3.21 Global Sales of Ebitux, 2004-2007
    • Table 3.22 Erbitux Market Sales Forecast, 2008-2023
    • Table 4.1 Oncology Market SWOT Analysis
    • Table 4.2 Cancer Cases in Leading EU Countries, 2002
    • Table 4.3 Cancer cases in the Key Emerging Countries, 2002
    • Table 4.4 Therapeutic Cancer Vaccines with Licenses or Predicted to Obtain them within the Forecast Period
    • Table 4.5 Prophylactic Cancer Vaccines Currently on the Market
    • Table 5.1 Revenues of the Top-10 Onclogy Companies, 2007
    • Table 5.2 Roche's Key Oncology Drugs ($m), 2007
    • Table 5.3 Roche's Phase III Oncology Pipeline, 2008
    • Table 5.4 Roche's Phase II Oncology Pipeline, 2008
    • Table 5.5 Roche's Phase I Oncology Pipeline, 2008
    • Table 5.6 Sanofi-Aventis' Key Oncology Drugs ($m), 2007
    • Table 5.7 Sanofi-Aventis' Phase III Oncology Pipeline, 2008
    • Table 5.8 Sanofi-Aventis' Phase II Oncology Pipeline, 2008
    • Table 5.9 Sanofi-Aventis' Phase I Oncology Pipeline, 2008
    • Table 5.10 Amgen's Key Oncology Drugs ($m), 2007
    • Table 5.11 Amgen's Phase III Oncology Pipeline, 2008
    • Table 5.12 Amgen's Phase II Oncology Pipeline, 2008
    • Table 5.13 Amgen's Phase I Oncology Pipeline, 2008
    • Table 5.14 Novartis' Key Oncology Drugs ($m), 2007
    • Table 5.15 Novartis' Phase III Oncology Pipeline, 2008
    • Table 5.16 Novartis' Phase II Oncology Pipeline, 2008
    • Table 5.17 Novartis' Phase I Oncology Pipeline, 2008
    • Table 5.18 AstraZeneca's Key Oncology Drugs ($m), 2007
    • Table 5.19 AstraZeneca's Oncology Product Extension Pipeline
    • Table 5.20 AstraZeneca's Phase III Oncology Pipeline, 2008
    • Table 5.21 AstraZeneca's Phase II Oncology Pipeline, 2008
    • Table 5.22 AstraZeneca's Phase I Oncology Pipeline, 2008
    • Table 5.23 J&J's Key Oncology Drugs ($m), 2007
    • Table 5.24 J&J's Phase III Oncology Pipeline, 2008
    • Table 5.25 J&J's Phase II Oncology Pipeline, 2008
    • Table 5.26 J&J's Phase I Oncology Pipeline, 2008
    • Table 5.27 Schering-Plough's Key Oncology Drugs ($m), 2007
    • Table 5.28 Schering-Plough's Phase III Oncology Pipeline, 2008
    • Table 5.29 Schering-Plough's Phase III Oncology Pipeline, 2008
    • Table 5.30 Schering-Plough's Phase III Oncology Pipeline, 2008
    • Table 5.31 Pfizer's Key Oncology Drugs ($m), 2007
    • Table 5.32 Pfizer's Phase III Oncology Pipeline, 2008
    • Table 5.33 Pfizer's Phase II Oncology Pipeline, 2008
    • Table 5.34 Pfizer's Phase I Oncology Pipeline, 2008
    • Table 5.35 Eli Lilly's Key Oncology Drugs ($m), 2007
    • Table 5.36 Eli Lilly's Phase III Oncology Pipeline, 2008
    • Table 5.37 Eli Lilly's Phase II Oncology Pipeline, 2008
    • Table 5.38 Eli Lilly's Phase II Oncology Pipeline, 2008
    • Table 5.39 Merck KGaA's Key Oncology Drugs ($m), 2007
    • Table 5.40 Merck KGaA's Phase III Oncology Pipeline, 2008
    • Table 5.41 Merck KGaA's Phase II Oncology Pipeline, 2008
    • Table 5.42 Merck KGaA's Phase I Oncology Pipeline, 2008
    • Table 6.1 Total Sales of All Oncology Therapeutic Classes, 2004-2007
    • Table 6.2 Total Sales of All Other Anti-Neoplastic Drugs, 2007
    • Table 6.3 Global Oncology Market: Total Sales, 2008-2023
    • Table 6.4 US Market Leads Sales in the Oncology Market, 2004-2007
    • Table 6.5 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
    • Table 6.6 US Oncology Market: Total Sales, 2008-2023
    • Table 6.7 Sales ($m) in Japan's Oncology Market by Therapeutic Class, 2004-2007
    • Table 6.8 Japan's Oncology Market: Total Sales, 2008-2023
    • Table 6.9 Leading EU Oncology Market Revenues, 2004-2007
    • Table 6.10 Sales ($m) in France Oncology Market by Therapeutic Class, 2004-2007
    • Table 6.11 France's Oncology Market: Total Sales, 2008-2023
    • Table 6.12 Sales ($m) in Germany's Oncology Market by Therapeutic Class, 2004-2007
    • Table 6.13 Germany's Oncology Market: Total Sales, 2008-2023
    • Table 6.14 Sales ($m) in Italy's Oncology Market by Therapeutic Class,2004-2007
    • Table 6.15 Italy's Oncology Market: Total Sales, 2008-2023
    • Table 6.16 Sales ($m) in Spain's Oncology Market by Therapeutic Class,2004-2007
    • Table 6.17 Spain's Oncology Market: Total Sales, 2008-2023
    • Table 6.18 Sales ($m) in UK's Oncology Market by Therapeutic Class, 2004-2007
    • Table 6.19 UK Oncology Market: Total Sales, 2008-2023
    • Table 6.20 Leading Emerging Markets for Anticancer Therapeutics, 2003-2006
    • Table 6.21 RoW Oncology Market: Total Sales, 2008-2023
  • List of Figures
    • Figure 2.1 Incidence of and Mortality from the Most Common Cancers Worldwide
    • Figure 2.2 Incidence of and Mortality from the Most Common Male Cancers
    • Figure 2.3 Incidence of and Mortality from the Most Common Female Cancers
    • Figure 2.4 Rates of Cancer Incidence and Mortality in Developing Nations
    • Figure 2.5 Rates of Cancer Incidence and Mortality in Developed Nations
    • Figure 2.6 Global Therapeutic Markets, 2007
    • Figure 2.7 Global Therapeutic Markets, 2007
    • Figure 2.8 Cancer Drugs Category Sales, 2007
    • Figure 2.9 Cancer Drugs Category Market Share, 2007
    • Figure 3.1 Top-10 Oncology Drugs: Total Sales, 2008-2023
    • Figure 3.2 Market Share of Top-10 Anti-Neoplastic Drugs, 2007
    • Figure 3.3 Global Sales of MabThera, 2004-2007
    • Figure 3.4 MabThera: Total Sales, 2008-2023
    • Figure 3.5 Global Sales of Herceptin, 2004-2007
    • Figure 3.6 Herceptin Market Sales Forecast 2008-2023
    • Figure 3.7 Global Sales of Avastin, 2004-2007
    • Figure 3.8 Avastin Market Sales Forecast 2008-2023
    • Figure 3.9 Global Sales of Glivec, 2004-2007
    • Figure 3.10 Glivec Market Sales Forecast 2008-2023
    • Figure 3.11 Global Sales of Taxotere, 2004-2007
    • Figure 3.12 Taxotere Market Sales Forecast 2008-2023
    • Figure 3.13 Global Sales of Eloxatin, 2004-2007
    • Figure 3.14 Eloxatin Market Sales Forecast 2008-2023
    • Figure 3.15 Global Sales of Arimidex, 2004-2007
    • Figure 3.16 Arimidex Market Sales Forecast, 2008-2023
    • Figure 3.17 Global Sales of Gemzar, 2004-2007
    • Figure 3.18 Gemzar Market Sales Forecast, 2008-2023
    • Figure 3.19 Global Sales of Casodex, 2004-2007
    • Figure 3.20 Casodex Market Sales Forecast, 2008-2023
    • Figure 3.21 Global Sales of Ebitux, 2004-2007
    • Figure 3.22 Erbitux Market Sales Forecast, 2008-2023
    • Figure 4.1 Spectrum of Present Unmet Needs in Cancer treatment
    • Figure 4.2 Factors to Drive Revenue Growth in the Oncology Market
    • Figure 4.3 Cancer Cases in Key EU Countries, 2002
    • Figure 4.4 Cancer cases in the Key Emerging Countries, 2002
    • Figure 4.5 Cancer cases in the Two Key Emerging Countries in Europe, 2002
    • Figure 5.1 Revenues of the Top-10 Onclogy Companies, 2007
    • Figure 5.2 Market Share for Top-10 Onclogy Companies, 2007
    • Figure 5.3 Roche's key Oncology Drugs ($m), 2007
    • Figure 5.4 Roche's key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.5 Roche Has Different Compounds in Phase III
    • Figure 5.6 Sanofi-Aventis' Key Oncology Drugs ($m), 2007
    • Figure 5.7 Sanofi-Aventis key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.8 Amgen's Key Oncology Drugs ($m), 2007
    • Figure 5.9 Amgen's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.10 Novartis' Key Oncology Drugs ($m), 2007
    • Figure 5.11 Novartis' Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.12 AstraZeneca's Key Oncology Drugs ($m), 2007
    • Figure 5.13 AstraZeneca's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.14 J&J's Key Oncology Drugs ($m), 2007
    • Figure 5.15 J&J's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.16 Schering-Plough's Key Oncology Drugs ($m), 2007
    • Figure 5.17 Schering-Plough's Key Oncology Drugs ($m), 2007
    • Figure 5.18 Pfizer's Key Oncology Drugs ($m), 2007
    • Figure 5.19 Pfizer's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.20 Eli Lilly's Key Oncology Drugs ($m), 2007
    • Figure 5.21 Eli Lilly's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 5.22 Merck KGaA's Key Oncology Drugs ($m), 2007
    • Figure 5.23 Merck KGaA's Key Oncology Drugs Therapeutic Share, 2007
    • Figure 6.1 Total Sales of All Oncology Therapeutic Classes, 2004-2007
    • Figure 6.2 Total Sales of All Oncology Therapeutic Classes, 2004-2007
    • Figure 6.3 Global Oncology Market Share, 2007
    • Figure 6.4 Global Oncology Market: Total Sales, 2008-2023
    • Figure 6.5 US Market Leads Sales inthe Oncology Market, 2004-2007
    • Figure 6.6 US Leads Oncology Market Share, 2007
    • Figure 6.7 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
    • Figure 6.8 US Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.9 US Oncology Market: Total Sales, 2008-2023
    • Figure 6.10 Japan's Oncology Market Revenues, 2004-2007
    • Figure 6.11 Sales ($m) in Japan's Oncology Market by Therapeutic Class,2004-2007
    • Figure 6.12 Japan's Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.13 Japan's Oncology Market: Total Sales, 2008-2023
    • Figure 6.14 Leading EU Oncology Market Share, 2007
    • Figure 6.15 France's Oncology Market Revenues, 2004-2007
    • Figure 6.16 Sales ($m) in France Oncology Market by Therapeutic Class, 2004-2007
    • Figure 6.17 France's Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.18 France Oncology Market: Total Sales, 2008-2023
    • Figure 6.19 Germany's Oncology Market Revenues, 2004-2007
    • Figure 6.20 Sales ($m) in Germany's Oncology Market by Therapeutic Class, 2004-2007
    • Figure 6.21 Germany's Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.22 Germany's Oncology Market: Total Sales, 2008-2023
    • Figure 6.23 Italy's Oncology Market Revenues, 2004-2007
    • Figure 6.24 Sales ($m) in Italy's Oncology Market by Therapeutic Class, 2004-2007
    • Figure 6.25 Italy's Oncology Market Revenues, 2004-2007
    • Figure 6.26 Italy's Oncology Market: Total Sales, 2008-2023
    • Figure 6.27 Spain's Oncology Market Revenues, 2004-2007
    • Figure 6.28 Sales ($m) in Spain's Oncology Market by Therapeutic Class,2004-2007
    • Figure 6.29 Spain's Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.30 Spain's Oncology Market: Total Sales, 2008-2023
    • Figure 6.31 UK's Oncology Market Revenues, 2004-2007
    • Figure 6.32 Sales ($m) in UK's Oncology Market by Therapeutic Class, 2004-2007
    • Figure 6.33 UK's Oncology Market Therapeutic Classes Share, 2007
    • Figure 6.34 UK's Oncology Market: Total Sales, 2008-2023
    • Figure 6.35 Leading Emerging Markets for Anticancer Therapeutics, 2003-2006
    • Figure 6.36 Leading Emerging Markets Oncology Therapeutics Classes Share,2006
  • Companies Listed
    • Abraxis
    • Amgen
    • AstraZeneca
    • AVAX
    • Baxter International
    • Bayer
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Burrill
    • Celgene
    • Cephalon
    • Chiron Corporation
    • Chugai
    • Daiichi Sankyo
    • Dendreon Corporation
    • Eisai
    • Eli Lilly
    • Genentech
    • GlaxoSmithKline
    • Hoffman-LaRoche
    • Hospira
    • ImClone Systems
    • Immunex Corporation
    • Intracel
    • Johnson&Johnson
    • JS LYG Hengrui
    • Kyowa Hakko
    • Melacine
    • Merck & Co
    • Merck KGaA
    • Novartis
    • OSI
    • Otsuka
    • Oxford BioMedica
    • Pfizer
    • Pierre Fabre
    • Plexxikon
    • PriceWaterHouseCooper
    • Provenge
    • Purdue
    • Mundipharma
    • Sanofi-Aventis
    • Schering-Plough
    • Servier
    • Shenzhen Wanle
    • Teva
    • TroVac
    • Valeant
    • World Health Organisation (WHO)
    • Wyeth
    • Yakult